Role of Melanocortin Receptors in the Regulation of Gouty Inflammation
| Autor: | Hetal B. Patel, Trinidad Montero-Melendez, Mauro Perretti |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
musculoskeletal diseases
Allopurinol Inflammatory arthritis Arthritis Gout Suppressants Injections Intra-Articular Mice Psoriatic arthritis Rheumatology medicine Animals Humans Arthritis Gouty business.industry Receptors Melanocortin medicine.disease Melanocortin 3 receptor Melanocortins Uric Acid Gout Disease Models Animal Drug development Rheumatoid arthritis Immunology Melanocortin Colchicine Crystallization business |
| Zdroj: | Current Rheumatology Reports. 13:138-145 |
| ISSN: | 1534-6307 1523-3774 |
| DOI: | 10.1007/s11926-011-0163-0 |
| Popis: | Gouty arthritis is a form of acute joint inflammation provoked by joint deposition of urate crystals. Although this acute pathology resolves after a few days, the marked degree of inflammation in the joint and--possibly more important to the patient--the excruciating pain it causes require proper therapeutic management. Often deemed a "poor sibling" of chronic joint pathologies such as rheumatoid arthritis and psoriatic arthritis, the increasing incidence of gout makes it a more palatable disease for novel drug discovery programs. This fact, associated with novel insights into the molecular mechanisms activated by the urate crystal deposition, is at the basis of new therapeutics under clinical development for gout, a valid example being the effective targeting of the proinflammatory cytokine interleukin-1. Here we briefly review the current status of antigout drug development and propose another target; our focus is on melanocortin receptor agonists as novel therapeutics for gout and inflammatory arthritides, a prototype of which, the adrenocorticotropic hormone, is already used in clinical settings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink